Based on the approval from Indian regulatory authorities, India’s Bharat Biotech is planning to launch its COVID-19 vaccine candidate in the second quarter of 2021.
The Indian biotechnology company had received initial approval from the Drugs Controller General of India to conduct late-stage trials for its vaccine candidate COVAXIN and informed about its plans to conduct recruitment and dosage for the Phase 3 trials in November.
This aforementioned trial will be conducted in 25 sites in 10-12 states and will provide two doses each for the vaccine and placebo recipients.
Based in Hyderabad, Bharat Biotech is developing the vaccine for coronavirus in collaboration with the Indian Council of Medical Research. The company is also in talks with more than 10 countries that have shown an interest in its potential COVID-19 vaccine.
Source: Reuters
